Biome Releases First Half FY2024 Results
● Biome reports record half year and quarterly sales revenue (H1FY24 $6.02m;
Q2FY24 $3.3m)
● FY24 revenue guidance upgraded to $12.5m in January 2024
● Biome signed landmark biological intellectual property agreement to
develop and solely own multiple novel probiotic strains in December 2023
● Biome announced new cholesterol-lowering probiotic, Biome Cholesterol™
Probiotic for release in H2FY24
● Biome successfully launched three new condition-specific live
biotherapeutic products, Biome Dental™ Probiotic, Biome Lax™ Probiotic
and Biome Recovery™ Probiotic in H1FY24
● Biome management reaffirms the company expects to achieve first positive
monthly EBITDA by June 2024
● January’s launch into the European health retail channel has commenced
with key distributor partners including CLF in the United Kingdom and
iiHealthfoods in the Republic of Ireland
● Biome reports gross margin increase to 60% as at 31 December 2023
Biome Releases First Half FY2024 Results● Biome reports record...
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
80.5¢ |
Change
-0.010(1.23%) |
Mkt cap ! $175.5M | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 83.0¢ | 80.0¢ | $286.3K | 352.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18793 | 79.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.5¢ | 20200 | 2 |
View Market Depth
| Last trade - 10.10am 10/09/2024 (20 minute delay) ? |
| BIO (ASX) Chart |